- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.02. | Skye links CB1-Wegovy combo to 22.3% weight loss after a year in extension of failed ph. 2 study | ||
| 02.02. | Roche's return to RNA continues with $1.7B deal for Sanegene program | ||
| 02.02. | Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease | ||
| 30.01. | Corcept submitted lead asset for approval despite FDA flagging risk of 'significant review issues' | ||
| 30.01. | Moderna's latest CMO steps down after barely a year | ||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | ||
| 30.01. | Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program | ||
| 30.01. | AstraZeneca returns to China's CSPC Pharma for $4.7B obesity deal | ||
| 30.01. | Moderna offloads late-stage rare disease drug to Recordati for $50M upfront | ||
| 29.01. | Formation Bio's China shopping spree continues with $500M biobucks autoimmune pact | ||
| 29.01. | Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine | ||
| 29.01. | Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials | ||
| 29.01. | Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout | ||
| 29.01. | AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities | ||
| 29.01. | Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor | ||
| 28.01. | Eikon sets $274M goal for upcoming stock market debut | ||
| 28.01. | FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling | ||
| 28.01. | CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern' | ||
| 28.01. | Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss | ||
| 28.01. | Boehringer channels mid-stage momentum into pivotal kidney disease trial | ||
| 27.01. | After patient death, FDA lifts hold on 1 of 2 late-stage trials testing Intellia's CRISPR therapy | ||
| 27.01. | Lisata reclaims China rights to solid tumor candidate ahead of acquisition | ||
| 27.01. | From gene therapies to ... firearms? Italian biotech makes unexpected strategic pivot | ||
| 27.01. | Boehringer pens €1.05B deal for Simcere's preclinical IBD bispecific | ||
| 27.01. | Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.